GEEN Biotechnology was founded in 2015. Our journey started by developing a synthetic viral plasmid, GeenOS, to run genetic circuits with maximum accuracy compared to their in silico design & simulations. Today we use a new version of the same genetic circuitry as the most powerful directed evolution technology designed to evolve therapeutic viruses with outstanding properties.
Our aim is to substitute conventional cancer therapies with a safer, personalization-friendly and a more effective alternative. We believe that this is only possible by unlocking the potential of the long-promised oncolytic virotherapy.
Oncolytic viruses are not naturally evolved as cancer therapeutics. Our approach is to redesign an evolutionary process for oncolytic viruses and transform their beneficial therapeutic side properties into their purposes.
Our technology comprises a piece of DNA where we define an engineered goal of evolution to the viruses and force them to learn how to activate a patient’s immune system against cancer without being recognized within the body.